Shenqu xiaoshi oral solution enhances digestive function and stabilizes the gastrointestinal microbiota of juvenile rats with infantile anorexia

Massa Medicata Fermentata (“Shenqu”) has long been applied in the treatment of indigestion in China; in fact, it is the active ingredient in the medicine Shenqu xiaoshi oral solution (SQXSOS). Based on robust clinical evidence, SQXSOS has shown efficacy in treating infantile anorexia (IFA). To inves...

Full description

Saved in:
Bibliographic Details
Published in:Journal of ethnopharmacology 2024-01, Vol.319, p.117112-117112, Article 117112
Main Authors: Zhao, Meng, Xiang, Ting, Dong, Zhikui, Liu, Guorui, Wang, Pengran, Qi, Xiaoxu, Hao, Qingqing, Han, Na, Liu, Zhihui, Li, Sikai, Yin, Jun, Zhai, Jianxiu
Format: Article
Language:English
Subjects:
Gastric microbiota
Infantile anorexia
Network pharmacology
Shenqu Xiaoshi oral solution
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Massa Medicata Fermentata (“Shenqu”) has long been applied in the treatment of indigestion in China; in fact, it is the active ingredient in the medicine Shenqu xiaoshi oral solution (SQXSOS). Based on robust clinical evidence, SQXSOS has shown efficacy in treating infantile anorexia (IFA). To investigate the underlying mechanisms by which SQXSOS treats IFA. The pharmacodynamic efficacy of SQXSOS was validated through a high-fat diet (HFD)-induced IFA model of juvenile rats, which share physiological similarities to two-year-old humans. Ultra-high-performance liquid chromatography coupled with time-of-flight mass spectrometry (UHPLC-TOF MS) was utilized to analyze the blood-dissolved components of SQXSOS in rats. After identification of the blood-dissolved components, the key components and target genes were predicted through network pharmacology analysis. To further validate the predicted key targets of the blood-dissolved components, RT-PCR and Western blotting were employed to measure the changes in their concentrations. Meanwhile, the efficacy of SQXSOS on the structure of gastrointestinal microbiota (GM) in IFA rats was investigated. SQXSOS, when administered to the IFA rats at a dosage equivalent to its clinical dose in humans (3.78 mL/kg/day), induced a significant increase in the gastric emptying rate (+1.9-fold) and small intestine advancement rate (+0.5-fold) compared to the IFA rats. Additionally, SQXSOS reversed the pathological changes observed in the serum levels of digestive functioning biochemicals (−32.4%～+250% compared to the model group, p 
ISSN:0378-8741
1872-7573
DOI:10.1016/j.jep.2023.117112